The proto-oncogene serine/threonine-protein kinases, Pim-1 and Pim-2, are enzymes involved in cytokine signaling and participate in various signal transduction pathways, including cell growth, differentiation, and apoptosis. Their overexpression has been implicated in prostate cancer, some forms of leukemia, and lymphoma. TCS PIM-1 1 is an ATP-competitive Pim-1 kinase inhibitor (IC50 = 50 nM) that displays selectivity over the related kinases, Pim-2 and MEK1/2 (IC50s = >20 μM).
